Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 9/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15859935 | 0.79 | KDM4E (0.55) | DDR1KDM4EALDH1A1MAPT | |
| SCHEMBL27083200 | 0.76 | ALDH1A1 (0.55) | KDM4EALDH1A1MAPT | |
| SCHEMBL347003 | 0.75 | DDR1 (0.42) | LTA4HDDR1KDM1AKDM4EALDH1A1 | |
| SCHEMBL4282318 | 0.73 | CYP2A13 (0.42) | KDM4EALDH1A1HRH3 | |
| Formic Acid SCHEMBL28291907 | 0.73 | KDM4E (0.54) | DDR1KDM4EALDH1A1MAPT | |
| SCHEMBL15381987 | 0.71 | DDR1 (0.49) | DDR1KDM1A | |
| SCHEMBL15687979 | 0.70 | NR1H2 (0.61) | DDR1 | |
| SCHEMBL589421 | 0.70 | NR1H2 (0.61) | DDR1 | |
| SCHEMBL589420 | 0.70 | NR1H2 (0.61) | DDR1 | |
| SCHEMBL274217 | 0.70 | NR1H2 (0.48) | DDR1KDM4EALDH1A1MAPTNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143716-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | claimed |
| US-20150313900-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | claimed |
| US-9061029-B2 | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | claimed |
| US-20140350037-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | claimed |
| US-20130267549-A1 | Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | claimed |
| US-20120289528-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | claimed |
| EP-2501384-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | Novartis AG (CH) | 2012-09-26 | — | — | EP | claimed |
| EP-2490690-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | Novartis AG (CH) | 2012-08-29 | — | — | EP | claimed |
| US-20120202836-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | claimed |
| US-20120015968-A1 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE LEUCINE ZIPPER-AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK) | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | claimed |
| JP-2011528015-A | — | — | 2011-11-10 | — | — | JP | claimed |
| WO-2011062927-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | claimed |
| US-20110124670-A1 | Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | claimed |
| WO-2011050120-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | claimed |
| EP-2300014-A1 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF FIBROSIS | Novartis AG (CH) | 2011-03-30 | — | — | EP | claimed |
| WO-2010007034-A1 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF FIBROSIS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | claimed |
| US-20170143716-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| US-20150313900-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| WO-2010100248-A1 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK) | NOVARTIS AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010007034-A1 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF FIBROSIS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350037-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | DDR2, DDR1, PDGFRA | LTA4H 3966/4885DDR1 2/4885KDM1A 1684/4885 |
| US-20120015968-A1 | USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE LEUCINE ZIPPER-AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK) | MELK, MINK1, ZFX | LTA4H 1938/4885DDR1 3377/4885KDM1A 1742/4885 |
| US-20120289528-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | DDR2, DDR1, PDGFRA | LTA4H 4493/4885DDR1 2/4885KDM1A 1733/4885 |
| US-20120202836-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | DDR2, DDR1, PDGFRA | LTA4H 4224/4885DDR1 2/4885KDM1A 2062/4885 |
| US-20150313900-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | DDR2, DDR1, PDGFRB | LTA4H 3818/4885DDR1 2/4885KDM1A 1046/4885 |
| US-20130267549-A1 | Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis | AGTR1, AGTR2, ACE | LTA4H 558/4885DDR1 1326/4885KDM1A 2805/4885 |
| US-20110124670-A1 | Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis | AGTR1, AGTR2, ACE | LTA4H 507/4885DDR1 1414/4885KDM1A 2877/4885 |
| US-20170143716-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | DDR2, DDR1, ABL2 | LTA4H 3869/4885DDR1 2/4885KDM1A 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.